CC
NVS icon

Centiva Capital’s Novartis NVS Stock Holding History

Centiva Capital’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,910
Closed -$245K – 1504
2025
Q3 		$245K Buy
+1,910
New +$233K ﹤0.01% 808
2025
Q1 		– Sell
-5,119
Closed -$498K – 1967
2024
Q4 		$498K Buy
5,119
+2,856
+126% +$305K 0.01% 826
2024
Q3 		$260K Sell
2,263
-2,098
-48% -$238K 0.01% 1667
2024
Q2 		$464K Sell
4,361
-5,743
-57% -$576K 0.01% 1201
2024
Q1 		$977K Buy
+10,104
New +$1.04M 0.02% 673
2022
Q1 		– Sell
-16,067
Closed -$1.41M – 1744
2021
Q4 		$1.41M Buy
16,067
+7,831
+95% +$650K 0.03% 471
2021
Q3 		$674K Sell
8,236
-579
-7% -$52.1K 0.04% 505
2021
Q2 		$804K Buy
+8,815
New +$785K 0.02% 657

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Centiva Capital's NVS Position: Q4 2025 in Review

Centiva Capital sold out of Novartis (NVS) in Q4 2025, closing a stake of 1,910 shares — an estimated $245K sold.

Centiva Capital first reported a position in NVS in Q2 2021 and held it in 8 quarters. The position peaked at $1.41M in Q4 2021. 1,510 funds tracked by Wall St. Rank hold NVS as of Q4 2025.

  • Centiva Capital reported no remaining Novartis position as of Q4 2025 after selling out during the quarter.
  • Centiva Capital sold 1,910 Novartis shares in Q4 2025, an estimated $245K.
  • Centiva Capital first reported a position in Novartis in Q2 2021 and held it in 8 quarters.
  • Centiva Capital's Novartis position peaked at $1.41M in Q4 2021.
  • 1,510 funds tracked by Wall St. Rank held Novartis as of Q4 2025.

Based on Centiva Capital's 13F filing for Q4 2025, filed 13 Feb 2026.